Mefloquine is an antimalarial medication with significant CNS effects. It can cause serious and potentially permanent neuropsychiatric side effects including anxiety, depression, hallucinations, psychosis, and suicidal ideation, occurring in approximately 1 in 10,000 users for prophylaxis. These effects may persist for months to years after discontinuation or be permanent. It is contraindicated in individuals with a history of psychiatric disorders, depression, anxiety disorders, psychosis, schizophrenia, or seizures. Not recommended for severe malaria.
Мефлохін molecular structure diagram from the DrugsPRO substance library.
Also known as: Lariam, Wr142490, Mephaquin, Wr-177602, RO 21-5998, Mefloquinum, Mefloquina
Classification
Chemical: Medicine
Tag: Antimalarial
Tag: Prescription-medication
Tag: Quinoline methanol derivative
Effects
Vertigo
Headache
Sleep Disturbances
Balance Problems
Nausea
Vomiting
Dizziness
Vivid Dreams
Nightmares
Anxiety
Depression
Paranoia
Visual Hallucinations
Auditory Hallucination
Tinnitus
Ringing
Open Eye Visuals
Routes of Administration
Oral
Dosage
Common: 250 mg weekly (prophylaxis); 1250 mg single dose (treatment)
Duration
Peak: 168-240 h
Harm Reduction
Check interactions before mixing substances, pay attention to dose spacing and hydration, and treat all dosage guidance as approximate rather than guaranteed safe.
Sources
Substance data is aggregated from the following public harm-reduction and reference sources.
This static page is intended as a readable non-JS and prerender-friendly library export.
Get the full DrugsPRO experience
Open the interactive DrugsPRO app for search, saved items, interactions, and deeper harm reduction tools.
Get the PRO test kit. The simple, quick and reliable drug checking test kit. Visit https://protestkit.eu
Mefloquine - довідник з речовин DrugsPRO
Mefloquine: Mefloquine is an antimalarial medication with significant CNS effects. It can cause serious and potentially permanent neuropsychiatric side effects including anxiety, depression, hallucinations, psychosis, and suicidal ideation, occurring in approximately 1 in 10,000 users for prophylaxi